Home / Health / FDA Rejects China-Invented Cancer Drug Ivonescimab
FDA Rejects China-Invented Cancer Drug Ivonescimab
16 Nov
Summary
- FDA rejected ivonescimab, a cancer drug invented in China.
- Drug failed to show statistically significant benefit in trials.
- Summit Therapeutics bought U.S. rights from Chinese Akeso Biopharma.

The U.S. Food and Drug Administration (FDA) has rejected ivonescimab, a first-of-its-kind cancer drug originating from China. This decision is a significant setback for a medicine that was seen as a symbol of China's advancement in drug development.
Summit Therapeutics, the Florida-based company pursuing U.S. market approval, announced the FDA's decision on Sunday. Summit had obtained the rights to the drug from Akeso Biopharma, the Chinese pharmaceutical firm that invented ivonescimab.
The application for approval was specifically for patients with advanced lung cancer. However, the FDA cited a lack of statistically significant benefit in prolonging patients' lives during the global clinical trial.
Summit's application was based on a study comparing ivonescimab combined with chemotherapy against chemotherapy alone in patients who had previously undergone targeted treatment. The trial indicated success in delaying cancer progression, but regulatory scrutiny focused on overall survival.
Summit had attempted to present additional analyses to the FDA to support its case, but these were insufficient to sway the regulators. The rejection underscores the stringent requirements for drug approval in the United States.